Abstract

Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications

Author(s): Gilbert John A

Issue: Sep/Oct 2009 - Veterinary Compounding

Page(s): 400-403

Download in electronic PDF format for $75
  • Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications Page 1
  • Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications Page 2
  • Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications Page 3
  • Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications Page 4

Abstract

The practice of pharmaceutical compounding may involve the dispensing of controlled substances, a subset of prescription drug products. In such cases, the Drug Enforcement Administration has authority to regulate and enforce pharmacy compounding in the U.S. through the Controlled Substances Act and Drug Enforcement Administration regulations, although the Drug Enforcement Administration expressly acknowledges that the agency does not establish medical standards or guidelines on the treatment of pain. There is a need to balance the interests of law enforcement in reducing the potential for prescription drug abuse without adversely affecting the need to ensure appropriate availability and access to pain medicine. Compounding pharmacies provide an important service to practitioners and their patients suffering from chronic pain and debilitating illness. Without access to pain medicine, a patient’s needs would go unmet, resulting in unnecessary pain and suffering.

Related Keywords

  • prescription drug abuse
  • controlled substances
  • U.S. Drug Enforcement Administration
  • DEA
  • law enforcement
  • Model Guidelines
  • pain medication
  • medical practice standards
  • online pharmacy
  • internet

Related Categories

  • LEGAL
  • PAIN MANAGEMENT

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2009
Pg. 400-403
Efforts to Combat Prescription Drug Abuse Should Not Limit Access to Compounded Pain Medications
Author(s): Gilbert John A
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
Nov/Dec 2011
Pg. 526-527
PostScription: Drug Disposal: Compounding Pharmacists' Involvement in the Prevention of Prescription Drug Misuse and Abuse
Author(s): Williams LaVonn A
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Nov/Dec 2012
Pg. 446-450
The Drug Enforcement Agency's Position on "Constructive Transfer" Under the Controlled Substances Act
Author(s): Pore R David
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Nov/Dec 2016
Pg. 457-458
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)
Author(s):
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Mar/Apr 2012
Pg. 94-96
View Sample
The International Academy of Compounding Pharmacists Stepping Up Efforts to Remedy Problems Caused by the U.S. Drug Enforcement Administration's "Constructive Transfer" Policy
Author(s): Miller David G
Nov/Dec 2012
Pg. 456-460
Drug Shortage Compounding: The Only Safe Medication Source in a Time of Crisis
Author(s): Lyon Joanna
Jan/Feb 2003
Pg. 21-23
Profile of a Practice: Ward Drug Company Diabetic Shoppe and Prescription Compounding Center
Author(s): Vail Jane
May/Jun 2005
Pg. 201-205
Combating Cardiovascular Disease with Compounded Medications -- Part 2: Clinical and Compounding Issues for Antihypertensive Drugs
Author(s): Harrington Catherine A, Cauffield Jacintha
Jan/Feb 2020
Pg. 30-36
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Author(s): Dillon L R
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
Jan/Feb 2005
Pg. 44-46
The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List")
Author(s): Allen Loyd V Jr, Ashworth Lisa D
May/Jun 2010
Pg. 200-203
Topical Medications for Orofacial Neuropathic Pain
Author(s): Bramwell Bethany L
Mar/Apr 2010
Pg. 131-133
Cop's Best Friend: Preventing the Illegal Distribution and Transportation of Prescription Drugs
Author(s): Burke John, Hill Jeff
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr